Biosimilars Market Research Report by Indication (Autoimmune Diseases, Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, and Infectious Diseases), by Product (Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, and Recombinant Peptides), by Manufacturing - Global Forecast to 2025 - Cumulative Impact of COVID-19
Market Statistics:
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.
1. The Global Biosimilars Market is expected to grow from USD 9,751.27 Million in 2020 to USD 27,747.42 Million by the end of 2025.
2. The Global Biosimilars Market is expected to grow from EUR 8,550.10 Million in 2020 to EUR 24,329.46 Million by the end of 2025.
3. The Global Biosimilars Market is expected to grow from GBP 7,601.05 Million in 2020 to GBP 21,628.95 Million by the end of 2025.
4. The Global Biosimilars Market is expected to grow from JPY 1,040,707.92 Million in 2020 to JPY 2,961,353.37 Million by the end of 2025.
5. The Global Biosimilars Market is expected to grow from AUD 14,160.14 Million in 2020 to AUD 40,292.95 Million by the end of 2025.
Market Segmentation & Coverage:
This research report categorizes the Biosimilars to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Indication, the Biosimilars Market studied across Autoimmune Diseases, Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Infectious Diseases, and Oncology.
Based on Product, the Biosimilars Market studied across Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, and Recombinant Peptides. The Recombinant Glycosylated Proteins further studied across Erythropoietin, Follitropin, and Monoclonal Antibodies. The Recombinant Non-Glycosylated Proteins further studied across Granulocyte Colony-Stimulating Factor, Insulin, Interferons, and Recombinant Human Growth Hormone. The Recombinant Peptides further studied across Calcitonin and Glucagon.
Based on Manufacturing, the Biosimilars Market studied across Contract Manufacturing and In-House Manufacturing.
Based on Geography, the Biosimilars Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Biosimilars Market including AMEGA Biotech S.A., Amgen Inc., Apotex Inc., Biosidus S.A., Bioton S.A., Innovent Biologics, Inc., JHL Biotech, Inc., LG Chem, Ltd., Merck Sharp & Dohme Corp., Mylan N.V., Pfizer Inc., and Sandoz International GmbH.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.
360iResearch FPNV Positioning Matrix:
The 360iResearch FPNV Positioning Matrix evaluates and categorizes the vendors in the Biosimilars Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
360iResearch Competitive Strategic Window:
The 360iResearch Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Biosimilars Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Biosimilars Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Biosimilars Market?
4. What is the competitive strategic window for opportunities in the Global Biosimilars Market?
5. What are the technology trends and regulatory frameworks in the Global Biosimilars Market?
6. What are the modes and strategic moves considered suitable for entering the Global Biosimilars Market?
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.
1. The Global Biosimilars Market is expected to grow from USD 9,751.27 Million in 2020 to USD 27,747.42 Million by the end of 2025.
2. The Global Biosimilars Market is expected to grow from EUR 8,550.10 Million in 2020 to EUR 24,329.46 Million by the end of 2025.
3. The Global Biosimilars Market is expected to grow from GBP 7,601.05 Million in 2020 to GBP 21,628.95 Million by the end of 2025.
4. The Global Biosimilars Market is expected to grow from JPY 1,040,707.92 Million in 2020 to JPY 2,961,353.37 Million by the end of 2025.
5. The Global Biosimilars Market is expected to grow from AUD 14,160.14 Million in 2020 to AUD 40,292.95 Million by the end of 2025.
Market Segmentation & Coverage:
This research report categorizes the Biosimilars to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Indication, the Biosimilars Market studied across Autoimmune Diseases, Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Infectious Diseases, and Oncology.
Based on Product, the Biosimilars Market studied across Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, and Recombinant Peptides. The Recombinant Glycosylated Proteins further studied across Erythropoietin, Follitropin, and Monoclonal Antibodies. The Recombinant Non-Glycosylated Proteins further studied across Granulocyte Colony-Stimulating Factor, Insulin, Interferons, and Recombinant Human Growth Hormone. The Recombinant Peptides further studied across Calcitonin and Glucagon.
Based on Manufacturing, the Biosimilars Market studied across Contract Manufacturing and In-House Manufacturing.
Based on Geography, the Biosimilars Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Biosimilars Market including AMEGA Biotech S.A., Amgen Inc., Apotex Inc., Biosidus S.A., Bioton S.A., Innovent Biologics, Inc., JHL Biotech, Inc., LG Chem, Ltd., Merck Sharp & Dohme Corp., Mylan N.V., Pfizer Inc., and Sandoz International GmbH.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.
360iResearch FPNV Positioning Matrix:
The 360iResearch FPNV Positioning Matrix evaluates and categorizes the vendors in the Biosimilars Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
360iResearch Competitive Strategic Window:
The 360iResearch Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Biosimilars Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Biosimilars Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Biosimilars Market?
4. What is the competitive strategic window for opportunities in the Global Biosimilars Market?
5. What are the technology trends and regulatory frameworks in the Global Biosimilars Market?
6. What are the modes and strategic moves considered suitable for entering the Global Biosimilars Market?
1. PREFACE
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
3. EXECUTIVE SUMMARY
3.1. Introduction
3.2. Market Outlook
3.3. Product Outlook
3.4. Manufacturing Outlook
3.5. Indication Outlook
3.6. Geography Outlook
3.7. Competitor Outlook
4. MARKET OVERVIEW
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. MARKET INSIGHTS
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing pressure to reduce healthcare expenditure
5.1.1.2. Growing demands of pharmaceutical drugs
5.1.1.3. Expiration of major patents during the forecast period
5.1.1.4. Supportive government initiative and awareness creating programs in the developing economies
5.1.1.5. Lower cost biosimilars drugs than original biologics
5.1.2. Restraints
5.1.2.1. Reluctance of physicians to prescribe biosimilars
5.1.2.2. Unawareness among patients and preference for brand
5.1.3. Opportunities
5.1.3.1. New indications and patent expiry of biologic products
5.1.3.2. Potential in emerging markets
5.1.3.3. Emergence of bio-betters drugs
5.1.4. Challenges
5.1.4.1. Stringent regulatory requirements adversely affecting investment in the biosimilars market
5.1.4.2. High investment required for research and development
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry
6. GLOBAL BIOSIMILARS MARKET, BY INDICATION
6.1. Introduction
6.2. Autoimmune Diseases
6.3. Blood Disorders
6.4. Chronic Diseases
6.5. Growth Hormone Deficiency
6.6. Infectious Diseases
6.7. Oncology
7. GLOBAL BIOSIMILARS MARKET, BY PRODUCT
7.1. Introduction
7.2. Recombinant Glycosylated Proteins
7.2.1. Erythropoietin
7.2.2. Follitropin
7.2.3. Monoclonal Antibodies
7.2.3.1. Adalimumab
7.2.3.2. Infliximab
7.2.3.3. Rituximab
7.3. Recombinant Non-Glycosylated Proteins
7.3.1. Granulocyte Colony-Stimulating Factor
7.3.2. Insulin
7.3.3. Interferons
7.3.3.1. Interferon-Alpha
7.3.3.2. Interferon-Beta
7.3.4. Recombinant Human Growth Hormone
7.4. Recombinant Peptides
7.4.1. Calcitonin
7.4.2. Glucagon
8. GLOBAL BIOSIMILARS MARKET, BY MANUFACTURING
8.1. Introduction
8.2. Contract Manufacturing
8.3. In-House Manufacturing
9. AMERICAS BIOSIMILARS MARKET
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. ASIA-PACIFIC BIOSIMILARS MARKET
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. South Korea
10.10. Thailand
11. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom
12. COMPETITIVE LANDSCAPE
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis
12.4. Competitor SWOT Analysis
12.5. Competitive Scenario
12.5.1. Merger & Acquisition
12.5.2. Agreement, Collaboration, & Partnership
12.5.3. New Product Launch & Enhancement
12.5.4. Investment & Funding
12.5.5. Award, Recognition, & Expansion
13. COMPANY USABILITY PROFILES
13.1. AMEGA Biotech S.A.
13.2. Amgen Inc.
13.3. Apotex Inc.
13.4. Biosidus S.A.
13.5. Bioton S.A.
13.6. Innovent Biologics, Inc.
13.7. JHL Biotech, Inc.
13.8. LG Chem, Ltd.
13.9. Merck Sharp & Dohme Corp.
13.10. Mylan N.V.
13.11. Pfizer Inc.
13.12. Sandoz International GmbH
14. APPENDIX
14.1. Discussion Guide
14.2. License & Pricing
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
3. EXECUTIVE SUMMARY
3.1. Introduction
3.2. Market Outlook
3.3. Product Outlook
3.4. Manufacturing Outlook
3.5. Indication Outlook
3.6. Geography Outlook
3.7. Competitor Outlook
4. MARKET OVERVIEW
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. MARKET INSIGHTS
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing pressure to reduce healthcare expenditure
5.1.1.2. Growing demands of pharmaceutical drugs
5.1.1.3. Expiration of major patents during the forecast period
5.1.1.4. Supportive government initiative and awareness creating programs in the developing economies
5.1.1.5. Lower cost biosimilars drugs than original biologics
5.1.2. Restraints
5.1.2.1. Reluctance of physicians to prescribe biosimilars
5.1.2.2. Unawareness among patients and preference for brand
5.1.3. Opportunities
5.1.3.1. New indications and patent expiry of biologic products
5.1.3.2. Potential in emerging markets
5.1.3.3. Emergence of bio-betters drugs
5.1.4. Challenges
5.1.4.1. Stringent regulatory requirements adversely affecting investment in the biosimilars market
5.1.4.2. High investment required for research and development
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry
6. GLOBAL BIOSIMILARS MARKET, BY INDICATION
6.1. Introduction
6.2. Autoimmune Diseases
6.3. Blood Disorders
6.4. Chronic Diseases
6.5. Growth Hormone Deficiency
6.6. Infectious Diseases
6.7. Oncology
7. GLOBAL BIOSIMILARS MARKET, BY PRODUCT
7.1. Introduction
7.2. Recombinant Glycosylated Proteins
7.2.1. Erythropoietin
7.2.2. Follitropin
7.2.3. Monoclonal Antibodies
7.2.3.1. Adalimumab
7.2.3.2. Infliximab
7.2.3.3. Rituximab
7.3. Recombinant Non-Glycosylated Proteins
7.3.1. Granulocyte Colony-Stimulating Factor
7.3.2. Insulin
7.3.3. Interferons
7.3.3.1. Interferon-Alpha
7.3.3.2. Interferon-Beta
7.3.4. Recombinant Human Growth Hormone
7.4. Recombinant Peptides
7.4.1. Calcitonin
7.4.2. Glucagon
8. GLOBAL BIOSIMILARS MARKET, BY MANUFACTURING
8.1. Introduction
8.2. Contract Manufacturing
8.3. In-House Manufacturing
9. AMERICAS BIOSIMILARS MARKET
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. ASIA-PACIFIC BIOSIMILARS MARKET
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. South Korea
10.10. Thailand
11. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom
12. COMPETITIVE LANDSCAPE
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis
12.4. Competitor SWOT Analysis
12.5. Competitive Scenario
12.5.1. Merger & Acquisition
12.5.2. Agreement, Collaboration, & Partnership
12.5.3. New Product Launch & Enhancement
12.5.4. Investment & Funding
12.5.5. Award, Recognition, & Expansion
13. COMPANY USABILITY PROFILES
13.1. AMEGA Biotech S.A.
13.2. Amgen Inc.
13.3. Apotex Inc.
13.4. Biosidus S.A.
13.5. Bioton S.A.
13.6. Innovent Biologics, Inc.
13.7. JHL Biotech, Inc.
13.8. LG Chem, Ltd.
13.9. Merck Sharp & Dohme Corp.
13.10. Mylan N.V.
13.11. Pfizer Inc.
13.12. Sandoz International GmbH
14. APPENDIX
14.1. Discussion Guide
14.2. License & Pricing
LIST OF TABLES
TABLE 1. CURRENCY CONVERSION RATES
TABLE 2. GLOBAL BIOSIMILARS MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 3. GLOBAL BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 4. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 5. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 6. GLOBAL BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 7. GLOBAL BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 8. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 9. GLOBAL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 10. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 11. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 12. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 13. GLOBAL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 14. GLOBAL BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 15. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 16. GLOBAL BIOSIMILARS MARKET SIZE, BY ADALIMUMAB, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 17. GLOBAL BIOSIMILARS MARKET SIZE, BY INFLIXIMAB, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 18. GLOBAL BIOSIMILARS MARKET SIZE, BY RITUXIMAB, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 19. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 20. GLOBAL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 21. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULIN, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 22. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 23. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-ALPHA, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 24. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-BETA, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 25. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT HUMAN GROWTH HORMONE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 26. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 27. GLOBAL BIOSIMILARS MARKET SIZE, BY CALCITONIN, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 28. GLOBAL BIOSIMILARS MARKET SIZE, BY GLUCAGON, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 29. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 30. GLOBAL BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 31. GLOBAL BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 32. AMERICAS BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 33. AMERICAS BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 34. AMERICAS BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 35. AMERICAS BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 36. ARGENTINA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 37. ARGENTINA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 38. ARGENTINA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 39. BRAZIL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 40. BRAZIL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 41. BRAZIL BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 42. CANADA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 43. CANADA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 44. CANADA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 45. MEXICO BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 46. MEXICO BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 47. MEXICO BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 48. UNITED STATES BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 49. UNITED STATES BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 50. UNITED STATES BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 51. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 52. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 53. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 54. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 55. AUSTRALIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 56. AUSTRALIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 57. AUSTRALIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 58. CHINA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 59. CHINA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 60. CHINA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 61. INDIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 62. INDIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 63. INDIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 64. INDONESIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 65. INDONESIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 66. INDONESIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 67. JAPAN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 68. JAPAN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 69. JAPAN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 70. MALAYSIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 71. MALAYSIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 72. MALAYSIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 73. PHILIPPINES BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 74. PHILIPPINES BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 75. PHILIPPINES BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 76. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 77. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 78. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 79. THAILAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 80. THAILAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 81. THAILAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 86. FRANCE BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 87. FRANCE BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 88. FRANCE BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 89. GERMANY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 90. GERMANY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 91. GERMANY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 92. ITALY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 93. ITALY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 94. ITALY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 95. NETHERLANDS BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 96. NETHERLANDS BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 97. NETHERLANDS BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 98. QATAR BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 99. QATAR BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 100. QATAR BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 101. RUSSIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 102. RUSSIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 103. RUSSIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 104. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 105. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 106. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 107. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 108. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 109. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 110. SPAIN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 111. SPAIN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 112. SPAIN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 113. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 114. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 115. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 116. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 117. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 118. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 119. GLOBAL BIOSIMILARS MARKET: SCORES
TABLE 120. GLOBAL BIOSIMILARS MARKET: BUSINESS STRATEGY
TABLE 121. GLOBAL BIOSIMILARS MARKET: PRODUCT SATISFACTION
TABLE 122. GLOBAL BIOSIMILARS MARKET: RANKING
TABLE 123. GLOBAL BIOSIMILARS MARKET: MERGER & ACQUISITION
TABLE 124. GLOBAL BIOSIMILARS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 125. GLOBAL BIOSIMILARS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 126. GLOBAL BIOSIMILARS MARKET: INVESTMENT & FUNDING
TABLE 127. GLOBAL BIOSIMILARS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 128. GLOBAL BIOSIMILARS MARKET: LICENSE & PRICING
TABLE 1. CURRENCY CONVERSION RATES
TABLE 2. GLOBAL BIOSIMILARS MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 3. GLOBAL BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 4. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 5. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 6. GLOBAL BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 7. GLOBAL BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 8. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 9. GLOBAL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 10. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 11. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 12. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 13. GLOBAL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 14. GLOBAL BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 15. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 16. GLOBAL BIOSIMILARS MARKET SIZE, BY ADALIMUMAB, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 17. GLOBAL BIOSIMILARS MARKET SIZE, BY INFLIXIMAB, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 18. GLOBAL BIOSIMILARS MARKET SIZE, BY RITUXIMAB, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 19. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 20. GLOBAL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 21. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULIN, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 22. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 23. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-ALPHA, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 24. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-BETA, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 25. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT HUMAN GROWTH HORMONE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 26. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 27. GLOBAL BIOSIMILARS MARKET SIZE, BY CALCITONIN, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 28. GLOBAL BIOSIMILARS MARKET SIZE, BY GLUCAGON, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 29. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 30. GLOBAL BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 31. GLOBAL BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 32. AMERICAS BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 33. AMERICAS BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 34. AMERICAS BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 35. AMERICAS BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 36. ARGENTINA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 37. ARGENTINA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 38. ARGENTINA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 39. BRAZIL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 40. BRAZIL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 41. BRAZIL BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 42. CANADA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 43. CANADA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 44. CANADA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 45. MEXICO BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 46. MEXICO BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 47. MEXICO BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 48. UNITED STATES BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 49. UNITED STATES BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 50. UNITED STATES BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 51. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 52. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 53. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 54. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 55. AUSTRALIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 56. AUSTRALIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 57. AUSTRALIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 58. CHINA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 59. CHINA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 60. CHINA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 61. INDIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 62. INDIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 63. INDIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 64. INDONESIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 65. INDONESIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 66. INDONESIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 67. JAPAN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 68. JAPAN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 69. JAPAN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 70. MALAYSIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 71. MALAYSIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 72. MALAYSIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 73. PHILIPPINES BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 74. PHILIPPINES BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 75. PHILIPPINES BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 76. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 77. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 78. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 79. THAILAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 80. THAILAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 81. THAILAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 86. FRANCE BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 87. FRANCE BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 88. FRANCE BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 89. GERMANY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 90. GERMANY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 91. GERMANY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 92. ITALY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 93. ITALY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 94. ITALY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 95. NETHERLANDS BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 96. NETHERLANDS BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 97. NETHERLANDS BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 98. QATAR BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 99. QATAR BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 100. QATAR BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 101. RUSSIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 102. RUSSIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 103. RUSSIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 104. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 105. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 106. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 107. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 108. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 109. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 110. SPAIN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 111. SPAIN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 112. SPAIN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 113. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 114. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 115. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 116. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 117. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 118. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 119. GLOBAL BIOSIMILARS MARKET: SCORES
TABLE 120. GLOBAL BIOSIMILARS MARKET: BUSINESS STRATEGY
TABLE 121. GLOBAL BIOSIMILARS MARKET: PRODUCT SATISFACTION
TABLE 122. GLOBAL BIOSIMILARS MARKET: RANKING
TABLE 123. GLOBAL BIOSIMILARS MARKET: MERGER & ACQUISITION
TABLE 124. GLOBAL BIOSIMILARS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 125. GLOBAL BIOSIMILARS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 126. GLOBAL BIOSIMILARS MARKET: INVESTMENT & FUNDING
TABLE 127. GLOBAL BIOSIMILARS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 128. GLOBAL BIOSIMILARS MARKET: LICENSE & PRICING
LIST OF FIGURES
FIGURE 1. GLOBAL BIOSIMILARS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL BIOSIMILARS MARKET: RESEARCH EXECUTION
FIGURE 3. GLOBAL BIOSIMILARS MARKET SIZE, 2020 VS 2025 (USD MILLION)
FIGURE 4. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2020 (USD MILLION)
FIGURE 5. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2020 (USD MILLION)
FIGURE 6. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2020 (USD MILLION)
FIGURE 7. GLOBAL BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
FIGURE 8. GLOBAL BIOSIMILARS MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 9. GLOBAL BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 10. GLOBAL BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 11. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 12. GLOBAL BIOSIMILARS MARKET: MARKET DYNAMICS
FIGURE 13. GLOBAL BIOSIMILARS MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 14. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2020 VS 2025 (%)
FIGURE 15. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2020 VS 2025 (USD MILLION)
FIGURE 16. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2025
FIGURE 17. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2020 VS 2025 (USD MILLION)
FIGURE 18. GLOBAL BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, 2020 VS 2025 (USD MILLION)
FIGURE 19. GLOBAL BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, 2020 VS 2025 (USD MILLION)
FIGURE 20. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2020 VS 2025 (USD MILLION)
FIGURE 21. GLOBAL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, 2020 VS 2025 (USD MILLION)
FIGURE 22. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2020 VS 2025 (USD MILLION)
FIGURE 23. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2020 VS 2025 (%)
FIGURE 24. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2020 VS 2025 (USD MILLION)
FIGURE 25. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2025
FIGURE 26. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2020 VS 2025 (USD MILLION)
FIGURE 27. GLOBAL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, 2020 VS 2025 (USD MILLION)
FIGURE 28. GLOBAL BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, 2020 VS 2025 (USD MILLION)
FIGURE 29. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2020 VS 2025 (USD MILLION)
FIGURE 30. GLOBAL BIOSIMILARS MARKET SIZE, BY ADALIMUMAB, 2020 VS 2025 (USD MILLION)
FIGURE 31. GLOBAL BIOSIMILARS MARKET SIZE, BY INFLIXIMAB, 2020 VS 2025 (USD MILLION)
FIGURE 32. GLOBAL BIOSIMILARS MARKET SIZE, BY RITUXIMAB, 2020 VS 2025 (USD MILLION)
FIGURE 33. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2020 VS 2025 (USD MILLION)
FIGURE 34. GLOBAL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR, 2020 VS 2025 (USD MILLION)
FIGURE 35. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULIN, 2020 VS 2025 (USD MILLION)
FIGURE 36. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2020 VS 2025 (USD MILLION)
FIGURE 37. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-ALPHA, 2020 VS 2025 (USD MILLION)
FIGURE 38. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-BETA, 2020 VS 2025 (USD MILLION)
FIGURE 39. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT HUMAN GROWTH HORMONE, 2020 VS 2025 (USD MILLION)
FIGURE 40. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2020 VS 2025 (USD MILLION)
FIGURE 41. GLOBAL BIOSIMILARS MARKET SIZE, BY CALCITONIN, 2020 VS 2025 (USD MILLION)
FIGURE 42. GLOBAL BIOSIMILARS MARKET SIZE, BY GLUCAGON, 2020 VS 2025 (USD MILLION)
FIGURE 43. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2020 VS 2025 (%)
FIGURE 44. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2020 VS 2025 (USD MILLION)
FIGURE 45. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2025
FIGURE 46. GLOBAL BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, 2020 VS 2025 (USD MILLION)
FIGURE 47. GLOBAL BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, 2020 VS 2025 (USD MILLION)
FIGURE 48. AMERICAS BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 49. AMERICAS BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 50. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 51. ARGENTINA BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 52. BRAZIL BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 53. CANADA BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 54. MEXICO BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 55. UNITED STATES BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 56. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 57. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 58. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 59. AUSTRALIA BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 60. CHINA BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 61. INDIA BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 62. INDONESIA BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 63. JAPAN BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 64. MALAYSIA BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 65. PHILIPPINES BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 66. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 67. THAILAND BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 68. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 69. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 70. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 71. FRANCE BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 72. GERMANY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 73. ITALY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 74. NETHERLANDS BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 75. QATAR BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 76. RUSSIA BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 77. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 78. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 79. SPAIN BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 80. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 81. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 82. GLOBAL BIOSIMILARS MARKET: 360IRESEARCH FPNV POSITIONING MATRIX
FIGURE 83. GLOBAL BIOSIMILARS MARKET: 360IRESEARCH MARKET SHARE ANALYSIS
FIGURE 84. GLOBAL BIOSIMILARS MARKET: COMPETITOR SWOT ANALYSIS
FIGURE 85. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL BIOSIMILARS MARKET, BY TYPE
FIGURE 1. GLOBAL BIOSIMILARS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL BIOSIMILARS MARKET: RESEARCH EXECUTION
FIGURE 3. GLOBAL BIOSIMILARS MARKET SIZE, 2020 VS 2025 (USD MILLION)
FIGURE 4. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2020 (USD MILLION)
FIGURE 5. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2020 (USD MILLION)
FIGURE 6. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2020 (USD MILLION)
FIGURE 7. GLOBAL BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
FIGURE 8. GLOBAL BIOSIMILARS MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 9. GLOBAL BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 10. GLOBAL BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 11. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 12. GLOBAL BIOSIMILARS MARKET: MARKET DYNAMICS
FIGURE 13. GLOBAL BIOSIMILARS MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 14. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2020 VS 2025 (%)
FIGURE 15. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2020 VS 2025 (USD MILLION)
FIGURE 16. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2025
FIGURE 17. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2020 VS 2025 (USD MILLION)
FIGURE 18. GLOBAL BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, 2020 VS 2025 (USD MILLION)
FIGURE 19. GLOBAL BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, 2020 VS 2025 (USD MILLION)
FIGURE 20. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2020 VS 2025 (USD MILLION)
FIGURE 21. GLOBAL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, 2020 VS 2025 (USD MILLION)
FIGURE 22. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY, 2020 VS 2025 (USD MILLION)
FIGURE 23. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2020 VS 2025 (%)
FIGURE 24. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2020 VS 2025 (USD MILLION)
FIGURE 25. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2025
FIGURE 26. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2020 VS 2025 (USD MILLION)
FIGURE 27. GLOBAL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, 2020 VS 2025 (USD MILLION)
FIGURE 28. GLOBAL BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, 2020 VS 2025 (USD MILLION)
FIGURE 29. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2020 VS 2025 (USD MILLION)
FIGURE 30. GLOBAL BIOSIMILARS MARKET SIZE, BY ADALIMUMAB, 2020 VS 2025 (USD MILLION)
FIGURE 31. GLOBAL BIOSIMILARS MARKET SIZE, BY INFLIXIMAB, 2020 VS 2025 (USD MILLION)
FIGURE 32. GLOBAL BIOSIMILARS MARKET SIZE, BY RITUXIMAB, 2020 VS 2025 (USD MILLION)
FIGURE 33. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2020 VS 2025 (USD MILLION)
FIGURE 34. GLOBAL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR, 2020 VS 2025 (USD MILLION)
FIGURE 35. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULIN, 2020 VS 2025 (USD MILLION)
FIGURE 36. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2020 VS 2025 (USD MILLION)
FIGURE 37. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-ALPHA, 2020 VS 2025 (USD MILLION)
FIGURE 38. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-BETA, 2020 VS 2025 (USD MILLION)
FIGURE 39. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT HUMAN GROWTH HORMONE, 2020 VS 2025 (USD MILLION)
FIGURE 40. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2020 VS 2025 (USD MILLION)
FIGURE 41. GLOBAL BIOSIMILARS MARKET SIZE, BY CALCITONIN, 2020 VS 2025 (USD MILLION)
FIGURE 42. GLOBAL BIOSIMILARS MARKET SIZE, BY GLUCAGON, 2020 VS 2025 (USD MILLION)
FIGURE 43. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2020 VS 2025 (%)
FIGURE 44. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2020 VS 2025 (USD MILLION)
FIGURE 45. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2025
FIGURE 46. GLOBAL BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, 2020 VS 2025 (USD MILLION)
FIGURE 47. GLOBAL BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, 2020 VS 2025 (USD MILLION)
FIGURE 48. AMERICAS BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 49. AMERICAS BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 50. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 51. ARGENTINA BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 52. BRAZIL BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 53. CANADA BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 54. MEXICO BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 55. UNITED STATES BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 56. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 57. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 58. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 59. AUSTRALIA BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 60. CHINA BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 61. INDIA BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 62. INDONESIA BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 63. JAPAN BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 64. MALAYSIA BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 65. PHILIPPINES BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 66. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 67. THAILAND BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 68. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 69. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 70. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 71. FRANCE BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 72. GERMANY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 73. ITALY BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 74. NETHERLANDS BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 75. QATAR BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 76. RUSSIA BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 77. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 78. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 79. SPAIN BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 80. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 81. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 82. GLOBAL BIOSIMILARS MARKET: 360IRESEARCH FPNV POSITIONING MATRIX
FIGURE 83. GLOBAL BIOSIMILARS MARKET: 360IRESEARCH MARKET SHARE ANALYSIS
FIGURE 84. GLOBAL BIOSIMILARS MARKET: COMPETITOR SWOT ANALYSIS
FIGURE 85. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL BIOSIMILARS MARKET, BY TYPE
